The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

151–175 of 470

  • SevereFDA (Drugs)·D-814-2015·2015-04-29

    Attix Pharmaceuticals Recalls Natamycin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Natamycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Natamycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-873-2015·2015-04-29

    Attix Pharmaceuticals Recalls Quetiapine Fumarate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Quetiapine Fumarate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Quetiapine Fumarate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-701-2015·2015-04-29

    Attix Pharmaceuticals Recalls Guanabenz Acetate Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Guanabenz Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Guanabenz Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-951-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vecuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vecuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vecuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-775-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mefloquine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mefloquine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Mefloquine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-877-2015·2015-04-29

    Attix Pharmaceuticals Recalls Reserpine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling reserpine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Reserpine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-891-2015·2015-04-29

    Sertraline HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Sertraline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sertraline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-523-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aprepitant API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Aprepitant active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Aprepitant active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-783-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methazolamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-572-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cephalexin Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cephalexin Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cephalexin Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-730-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imatinib Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Imatinib Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imatinib Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-774-2015·2015-04-29

    Attix Pharmaceuticals Recalls Meclofenoxate HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Meclofenoxate HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Meclofenoxate HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-861-2015·2015-04-29

    Attix Pharmaceuticals Recalls Prilocaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Prilocaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Prilocaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-919-2015·2015-04-29

    Attix Pharmaceuticals Recalls Terbinafine Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Terbinafine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Terbinafine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-781-2015·2015-04-29

    Attix Pharmaceuticals Recalls Metformin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Metformin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Metformin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-555-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcipotriene Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Calcipotriene active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcipotriene active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-566-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cefadroxil Monohydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cefadroxil Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cefadroxil Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-642-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline Hyclate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline Hyclate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline Hyclate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-867-2015·2015-04-29

    Progesterone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling progesterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-859-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pregabalin Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling pregabalin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pregabalin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-527-2015·2015-04-29

    Attix Pharmaceuticals Recalls Atomoxetine HCl Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Atomoxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Atomoxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-918-2015·2015-04-29

    Attix Pharmaceuticals Recalls Temozolomide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Temozolomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Temozolomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-595-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clomipramine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clomipramine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clomipramine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-576-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloramphenicol Palmitate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloramphenicol Palmitate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chloramphenicol Palmitate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-525-2015·2015-04-29

    Artesunate API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Artesunate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Artesunate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide